The scale of the problem the guidelines are meant to address is staggering. Osteoporosis, a disorder in which low bone mass and deteriorating bone microarchitecture render skeletons dangerously fragile, currently affects roughly one in three women and one in five men over the age of 50 worldwide. A 2022 meta-analysis put global prevalence at 19.7 percent, with significantly higher rates in low- and middle-income countries. In China, a recent systematic review estimated that 13.5 percent of adults aged 20 to 89 had the disease under World Health Organization diagnostic criteria as of 2020. Because the condition is silent until a bone breaks, it is chronically underdiagnosed: approximately half of women and a fifth of men over 50 are expected to sustain an osteoporosis-related fracture, and by 2050 half of all hip fractures on Earth are projected to occur in Asia, with China bearing a disproportionate share of the burden.

The financial stakes are equally stark. Annual costs of osteoporosis-related fractures in China are projected to reach 25.43 billion US dollars by 2050 and to keep climbing as the population ages. Yet unlike the United Kingdom’s Royal College of Physicians or the United States’ Bone Health and Osteoporosis Foundation, which each issued a single authoritative national guideline, China has no universally recognised standard. The first mainland Chinese guideline appeared in 2006, but since then dozens of professional societies spanning orthopaedics, endocrinology, geriatrics, rehabilitation medicine, radiology, general practice, and traditional Chinese medicine have produced their own documents, each reflecting a different disciplinary perspective.

To map this landscape, researchers led by Ting Wei of Western Sydney University systematically searched English-language databases including Medline, Embase, the Cochrane Library, and Web of Science, alongside Chinese databases such as the China National Knowledge Infrastructure and Wanfang, and the websites of Chinese government bodies including the National Health Commission. From 8,100 records published up to 13 August 2026, independent reviewers screened titles, abstracts, and full texts, ultimately including 32 guidelines produced by more than 60 professional societies. Twenty-nine originated in mainland China, two in Hong Kong, and one in Taiwan, and 18 of the 32 appeared between 2022 and 2026, reflecting an accelerating output of guidance documents. Each guideline was appraised with the AGREE II instrument, the international standard for evaluating the methodological quality of clinical guidance.

The review found genuine consensus on fundamentals. All guidelines that addressed diagnosis endorsed dual-energy X-ray absorptiometry, or DXA, as the diagnostic tool of choice for measuring bone mineral density, and the guidelines broadly agreed on the definition of osteoporosis, its diagnostic criteria, and core prevention strategies such as calcium and vitamin D supplementation, exercise, dietary modification, and smoking cessation. Pharmacological and non-pharmacological approaches featured across the board: calcium and vitamin D appeared in 94 percent of guidelines, physical exercise in 91 percent, and patient education in 63 percent. Traditional Chinese medicine, aimed at tonifying the kidney and yang, strengthening the spleen and bones, and promoting circulation, was recommended in two-thirds of all guidelines, a distinctive feature of the Chinese context that has no equivalent in Western guidance.

Beneath this surface agreement, however, lay significant discordance. Bisphosphonates, the workhorse antiresorptive drugs, were recommended in every guideline addressing pharmacological therapy, yet only six explicitly identified them as first-line treatment, whereas US and UK guidelines are unambiguous on this point. Newer agents showed a striking temporal gradient: denosumab was recommended in all guidelines published from 2022 onwards, while romosozumab, a sclerostin inhibitor with both bone-forming and antiresorptive effects, first appeared in 2021 and became common from 2023, tracking its regulatory approval in mainland China in May 2026. More troubling, of 17 guidelines recommending denosumab, only three addressed the critical need for follow-on antiresorptive therapy after discontinuation, despite international evidence that stopping the drug triggers rebound bone turnover, rapid bone loss, and increased vertebral fracture risk.

Two systemic gaps separated Chinese guidance from its international counterparts. Fracture liaison services, coordinated multidisciplinary programmes that identify patients after a first fracture and initiate treatment to prevent the next one, were recommended in only nine guidelines, or 28 percent, even though such services demonstrably reduce re-fracture risk, mortality, and costs, and are standard recommendations in the US and UK. Health economic evaluation fared even worse: only two guidelines considered cost-effectiveness at all, despite Chinese analyses suggesting that zoledronate becomes cost-effective at a 10-year fracture probability above 7 percent and that drug-specific thresholds could rationally guide treatment initiation. In a country where fewer than one DXA machine exists per million people, the review also noted promising alternatives, including opportunistic quantification of bone density from CT scans already performed for other reasons, an approach shown to be feasible in a nationwide study of nearly 70,000 Chinese adults and cost-effective compared with DXA.

The AGREE II appraisal exposed deeper methodological weaknesses. Guidelines scored well on scope and purpose, with a mean of 87.8 percent, and on clarity of presentation at 77.8 percent, but collapsed on rigour of development, which averaged just 42.1 percent, and on applicability, the lowest domain at 29.0 percent. Only 14 of the 32 guidelines described systematic methods for searching evidence and formulating recommendations, only seven incorporated patient or consumer input, and merely two provided clear statements of independence from funding or sponsorship. Nineteen guidelines graded their evidence, but most offered little detail on how those grades were assigned, making it difficult to compare the strength of one recommendation against another.

The review also flagged a striking gender blind spot. Only one guideline focused specifically on osteoporosis in men, even though men suffer higher mortality after osteoporotic fractures than women and are more frequently underdiagnosed and undertreated. The evidence base itself is skewed: 64 percent of registered osteoporosis trials include only women, and even in mixed-sex trials women dominate enrolment, leaving treatment efficacy in men often inferred from surrogate bone density measures rather than actual fracture outcomes.

The authors conclude that China needs a more coherent national guideline built on systematic evidence grading, locally generated research, robust economic evaluation, and widespread implementation of fracture liaison services. With fracture costs heading toward 25 billion dollars annually and half the world’s hip fractures soon expected in Asia, the country’s fractured guideline landscape, ironically mirroring the disease it treats, may prove as consequential as any single clinical recommendation it contains.

Subject of Research: Consistency and quality of clinical practice guidelines for osteoporosis management in China

Article Title: Clinical guidelines for the management of osteoporosis in China: a systematic review

Article References: Clinical guidelines for the management of osteoporosis in China: a systematic review. (n.d.). https://doi.org/10.3389/fendo.2026.1943964

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1943964

Keywords: osteoporosis, clinical guidelines, China, systematic review, AGREE II, fracture liaison services, DXA, bisphosphonates, denosumab, health economics, ageing population, traditional Chinese medicine